News from durect corporation A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 13, 2023, 16:05 ET DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update

...

Nov 09, 2023, 16:30 ET DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update

DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the...

Nov 07, 2023, 16:01 ET DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality

Compelling efficacy signal in favor of larsucosterol in the key secondary endpoint of mortality at 90 days. Clinically relevant reduction in 90-day...

Sep 07, 2023, 07:00 ET DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

DURECT Corporation (Nasdaq: DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the...

Aug 31, 2023, 16:30 ET DURECT Corporation Announces Presentations in Upcoming Investor Conferences

DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver...

Aug 09, 2023, 16:05 ET DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2023 and provided a corporate update. "We are ...

Aug 03, 2023, 16:30 ET DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update

DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver...

Jul 20, 2023, 08:00 ET DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of ...

Jun 07, 2023, 06:00 ET DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company developing epigenetic therapies for the treatment of acute organ injuries and chronic...

May 08, 2023, 16:05 ET DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2023 and provided a corporate update. "We...

May 01, 2023, 19:03 ET DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8

DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2023 financial results and host a conference call after the...

Apr 27, 2023, 17:11 ET DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis

DURECT Corporation (Nasdaq: DRRX) today announced it will host a Key Opinion Leader ("KOL") event on Alcohol-Associated Hepatitis on May 16th in New...

Apr 25, 2023, 18:45 ET DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference

DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO, will participate in a fireside chat hosted by Ed Arce,...

Apr 10, 2023, 06:00 ET DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis

DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic modulator programs for the treatment of acute organ...

Mar 21, 2023, 16:30 ET DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board

DURECT Corporation (Nasdaq: DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023. Ms....

Mar 09, 2023, 08:30 ET DURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference

DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO and additional members of the management team will...

Mar 07, 2023, 16:05 ET DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2022 and provided a corporate...

Feb 28, 2023, 18:07 ET DURECT Corporation to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7

DURECT Corporation (Nasdaq: DRRX) today announced that it will report its fourth quarter and full year 2022 financial results and host a conference...

Feb 03, 2023, 17:17 ET DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants

DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company focused on developing its epigenetic regulator program for the treatment of ...

Nov 28, 2022, 18:46 ET DURECT Announces 1-for-10 Reverse Stock Split

DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ...

Nov 02, 2022, 16:05 ET DURECT Corporation Reports Third Quarter 2022 Financial Results and Update of Programs

DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended September 30, 2022 and provided a corporate update....

Oct 26, 2022, 08:30 ET DURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2

DURECT Corporation (Nasdaq: DRRX) today announced that it will report its third quarter 2022 financial results and host a conference call after the...

Oct 06, 2022, 08:30 ET DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial

DURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic regulator programs for the treatment of acute organ...

Sep 26, 2022, 08:30 ET Innocoll and DURECT Announce U.S. launch of POSIMIR®

Innocoll Pharmaceuticals Limited, a commercial-stage biotechnology company and portfolio business of Gurnet Point Capital, and DURECT Corporation...

Sep 06, 2022, 08:00 ET DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO will be presenting virtually at the H.C. Wainwright 24th ...